
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/317110/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunohistochemical Distinction Between Merkel Cell Carcinoma and Small Cell Carcinoma of the Lung. American Journal of Dermatopathology, 2006, 28, 99-104.	0.3	235
2	Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Annals of Oncology, 2012, 23, 427-435.	0.6	220
3	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Research and Treatment, 2011, 128, 447-456.	1.1	169
4	A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 1009-1021.	1.1	85
5	Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study. BMC Cancer, 2008, 8, 234.	1.1	84
6	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment, 2012, 134, 353-362.	1.1	82
7	Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation. Cancer Investigation, 2008, 26, 784-793.	0.6	66
8	A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 649-660.	1.1	61
9	Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel. PLoS ONE, 2012, 7, e37946.	1.1	54
10	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget, 2016, 7, 5074-5087.	0.8	54
11	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	1.1	48
12	Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemotherapy and Pharmacology, 2013, 71, 245-255.	1.1	48
13	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Journal of Translational Medicine, 2012, 10, 10.	1.8	46
14	Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer, 2009, 9, 339.	1.1	41
15	Detection of Helicobacter pylori in raw bovine milk by fluorescence in situ hybridization (FISH). International Journal of Food Microbiology, 2011, 151, 252-256.	2.1	41
16	Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer. Oncology, 2009, 76, 275-285.	0.9	37
17	Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Research and Treatment, 2011, 127, 179-193.	1.1	36
18	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. ESMO Open, 2019, 4, e000474.	2.0	34

MATTHEOS BOBOS

#	Article	IF	CITATIONS
19	Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. Journal of Translational Medicine, 2012, 10, 212.	1.8	32
20	EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. Journal of Cancer Research and Clinical Oncology, 2014, 140, 737-748.	1.2	30
21	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget, 2016, 7, 32731-32753.	0.8	30
22	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology, 2009, 2009, 1-17.	0.6	29
23	Second primary melanomas in a cohort of 977 melanoma patients within the first 5Âyears of monitoring. Journal of the American Academy of Dermatology, 2020, 82, 398-406.	0.6	29
24	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer, 2013, 13, 163.	1.1	27
25	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast, 2014, 23, 234-243.	0.9	26
26	Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. Breast, 2008, 17, 80-84.	0.9	25
27	A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. Journal of Neurology, 2013, 260, 1469-1480.	1.8	25
28	Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlentherapie Und Onkologie, 2014, 190, 636-645.	1.0	25
29	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. Journal of Translational Medicine, 2016, 14, 136.	1.8	25
30	Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Research, 2011, 31, 3007-18.	0.5	25
31	Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Research, 2012, 32, 1273-81.	0.5	25
32	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. Journal of Experimental and Clinical Cancer Research, 2012, 31, 77.	3.5	23
33	Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. BMC Clinical Pathology, 2013, 13, 1.	1.8	23
34	Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. Oral Oncology, 2014, 50, 298-305.	0.8	23
35	Sialadenoma papilliferum of bronchus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 695-699.	1.4	22
36	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemotherapy and Pharmacology, 2012, 69, 533-546.	1.1	22

#	Article	IF	CITATIONS
37	A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. World Journal of Surgical Oncology, 2008, 6, 137.	0.8	21
38	Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2013, 34, 268-272.	0.6	21
39	In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. PLoS ONE, 2014, 9, e99131.	1.1	21
40	Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. Anticancer Research, 2014, 34, 4949-62.	0.5	21
41	Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Annals of Oncology, 2012, 23, 2146-2153.	0.6	20
42	Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. PLoS ONE, 2018, 13, e0208221.	1.1	19
43	Challenges in sarcoidosis and sarcoidâ€like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case. Dermatologic Therapy, 2021, 34, e14618.	0.8	19
44	Primary pancreatic anaplastic large cell lymphoma, ALK negative: A case report. World Journal of Gastroenterology, 2005, 11, 6221.	1.4	19
45	Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. Journal of Oncology, 2010, 2010, 1-10.	0.6	18
46	Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. Clinical Breast Cancer, 2010, 10, 230-237.	1.1	17
47	Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Research, 2009, 29, 529-38.	0.5	17
48	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Annals of Oncology, 2012, 23, 2725-2730.	0.6	16
49	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment, 2016, 158, 307-321.	1.1	16
50	Profiling immunohistochemical expression of NOTCH1–3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. Clinical and Experimental Metastasis, 2012, 29, 603-614.	1.7	15
51	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOC) validation study. Journal of Translational Medicine, 2015, 13, 171.	1.8	15
52	Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Journal of Neuro-Oncology, 2017, 134, 443-451.	1.4	15
53	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). PLoS ONE, 2013, 8, e70634.	1.1	15
54	Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Research, 2006, 26, 4675-86.	0.5	15

MATTHEOS BOBOS

#	Article	IF	CITATIONS
55	Solitary fibrous tumor of the tongue: case report and literature review. International Journal of Oral and Maxillofacial Surgery, 2008, 37, 1067-1069.	0.7	14
56	Protein expression patterns of cell cycle regulators in operable breast cancer. PLoS ONE, 2017, 12, e0180489.	1.1	14
57	Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. Anticancer Research, 2013, 33, 2139-45.	0.5	14
58	Molecular detection of Helicobacter pylori in a large Mediterranean river, by direct viable count fluorescent in situ hybridization (DVC-FISH). Journal of Water and Health, 2014, 12, 868-873.	1.1	13
59	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. BMC Clinical Pathology, 2014, 14, 28.	1.8	13
60	Prevalent somatic <i>BRCA1</i> mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. International Journal of Cancer, 2018, 142, 66-80.	2.3	13
61	Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. Cancer Genomics and Proteomics, 2018, 15, 461-471.	1.0	13
62	Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer. Cancer Genomics and Proteomics, 2019, 16, 195-206.	1.0	13
63	Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial. PLoS ONE, 2013, 8, e69256.	1.1	12
64	Dermoscopic predictors to discriminate between in situ and early invasive lentigo maligna melanoma: A retrospective observational study. Journal of the American Academy of Dermatology, 2020, 83, 269-271.	0.6	11
65	Eccrine syringofibroadenoma treated with carbon dioxide laser. Clinical and Experimental Dermatology, 2009, 34, 261-263.	0.6	9
66	HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. Archives of Gynecology and Obstetrics, 2014, 290, 1231-1237.	0.8	9
67	p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab. Pathology and Oncology Research, 2015, 21, 273-282.	0.9	9
68	Heart and lymphoma: An unusual case of secondary cardiac lymphoma manifested through presyncope and syncope episodes and atrial flutter. Hellenic Journal of Cardiology, 2018, 59, 182-185.	0.4	9
69	Renal Cell Carcinoma Antigen Expression in Primary Cutaneous Endocrine Mucinous Carcinomas: A Case Series of 14 Patients and Review of the Literature. American Journal of Dermatopathology, 2019, 41, 571-577.	0.3	9
70	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Clinical Breast Cancer, 2018, 18, 53-62.e3.	1.1	8
71	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. Clinical Breast Cancer, 2019, 19, 113-125.e4.	1.1	8
72	Complete response of locally advanced basosquamous carcinoma to vismodegib in two patients. European Journal of Dermatology, 2019, 29, 102-104.	0.3	8

#	Article	IF	CITATIONS
73	Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. American Journal of Cancer Research, 2018, 8, 2-15.	1.4	7
74	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. Cancer Chemotherapy and Pharmacology, 2015, 75, 1289-1301.	1.1	6
75	Crizotinib Failure in a <i>TPM4-ALK</i> –Rearranged Inflammatory Myofibroblastic Tumor With an Emerging <i>ALK</i> Kinase Domain Mutation. JCO Precision Oncology, 2017, 1, 1-7.	1.5	6
76	Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical Oncology, 2018, 35, 101.	1.2	6
77	Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer. Anticancer Research, 2014, 34, 6495-503.	0.5	6
78	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. Anticancer Research, 2016, 36, 2365-78.	0.5	6
79	Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts. International Journal of Surgical Pathology, 2016, 24, 347-352.	0.4	5
80	Clinicopathologically problematic melanocytic tumors: a case-based review. Dermatology Practical and Conceptual, 2018, 8, 306-313.	0.5	5
81	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. Acta Oncológica, 2021, 60, 785-793.	0.8	5
82	Dermoscopy of Spitz/Reed naevi and management. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 457-465.	0.8	5
83	Disease evolution and heterogeneity in bilateral breast cancer. American Journal of Cancer Research, 2016, 6, 2611-2630.	1.4	5
84	Immunohistochemical investigation of CD34 antigen in male breast carcinoma. Clinical and Experimental Medicine, 2007, 7, 122-126.	1.9	4
85	Prognostic significance of <scp>WNT</scp> and hedgehog pathway activation markers in cancer of unknown primary. European Journal of Clinical Investigation, 2015, 45, 1145-1152.	1.7	4
86	Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. PLoS ONE, 2018, 13, e0207707.	1.1	4
87	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics and Proteomics, 2020, 17, 277-290.	1.0	4
88	Dermoscopic predictors of melanoma arising in small- and medium-sized congenital nevi. Journal of the American Academy of Dermatology, 2021, 84, 1703-1705.	0.6	4
89	Genetic Variations of <i>VEGFA</i> Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma. Anticancer Research, 2020, 40, 677-688.	0.5	4
90	Aberrant CCND1 copies and cyclin D1 mRNA expression do not result in the production of functional cyclin D1 protein in anaplastic large cell lymphoma. Histology and Histopathology, 2009, 24, 1035-48.	0.5	4

#	Article	IF	CITATIONS
91	In situdetection of hTERT variants in anaplastic large cell lymphoma. Leukemia and Lymphoma, 2006, 47, 1639-1650.	0.6	3
92	Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. PLoS ONE, 2014, 9, e103707.	1.1	3
93	Intact or Broken-apart RNA. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 60-70.	0.6	3
94	Thoracic duct cyst of posterior mediastinum: a "challenging―differential diagnosis. Annals of Translational Medicine, 2016, 4, 166-166.	0.7	3
95	Coincidence of thymoma and breast cancer and in a 56-year-old female patient. Annals of Translational Medicine, 2016, 4, 446-446.	0.7	3
96	Dermoscopy of poikilodermatous mycosis fungoides: A case escaping diagnosis for three decades. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 250-252.	0.7	3
97	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	1.0	2
98	Dermatoscopy of melanoma according to type, anatomic site and stage. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.1	2
99	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. Histology and Histopathology, 2015, 30, 1129-41.	0.5	2
100	Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer. Annals of Oncology, 2016, 27, vi32.	0.6	1
101	Dermoscopy of papuloerythroderma of Ofuji. Photodermatology Photoimmunology and Photomedicine, 2019, 35, 127-128.	0.7	1
102	Tumor infiltrating lymphocytes and hydrophobic amino acid changes in HER2-positive metastatic breast cancer Journal of Clinical Oncology, 2016, 34, 592-592.	0.8	1
103	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. Oncology Letters, 2021, 23, 23.	0.8	1
104	Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. Cancer Research and Treatment, 2021, , .	1.3	1
105	In response to Dr. Han's comments. Cancer Chemotherapy and Pharmacology, 2011, 67, 245-245.	1.1	0
106	Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study. Annals of Oncology, 2012, 23, ix213.	0.6	0
107	Aberrant ALK1 Mrna Expression Patterns are Associated with Poor Prognosis in Non-Small Cell Lung Cancer (NSCLC) Patients. A Hellenic Cooperative Oncology Group Study. Annals of Oncology, 2012, 23, ix430-ix431.	0.6	0
108	Activation Status and Prognostic Significance of the Wnt/B Catenin and Hedgehog/Smoothened Signalling Pathways in Patients with Cancer of Unknown Primary (Cup): a Translational Research Study of the Hellenic Cooperative Oncology Group (Hecog). Annals of Oncology, 2014, 25, iv396.	0.6	0

#	Article	IF	CITATIONS
109	Patient-private disease evolution and heterogeneity in bilateral breast cancer. Annals of Oncology, 2016, 27, vi54.	0.6	Ο
110	Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients. Annals of Oncology, 2016, 27, vi333.	0.6	0
111	Intrinsic tumor features underlying clinical subtype discordance in early breast cancer. Annals of Oncology, 2017, 28, v55-v56.	0.6	Ο
112	Abstract P2-09-15: TOP2A and DARPP32 Are Associated with Response to Trastuzumab-Based Treatment of HER2-Positive Advanced Breast Cancer (ABC). , 2010, , .		0
113	Abstract 5554: Tumor tissue dissection for gene expression assessments in translational research studies. , 2012, , .		Ο
114	ESR1 gene amplification and protein expression in 946 patients with resected breast cancer: AÂHellenicÂCooperativeÂOncologyÂGroup (HeCOG) translational research study Journal of Clinical Oncology, 2012, 30, 592-592.	0.8	0
115	In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients Journal of Clinical Oncology, 2012, 30, 573-573.	0.8	0
116	Expression Profiling of 21 Biomolecules in Locally Advanced Nasopharyngeal Carcinomas (LA-NPC) of Caucasian Patients Treated with Chemotherapy or Chemo-Radiotherapy (CRT) in the Context of a Hellenic Cooperative Oncology Group Randomized Trial. Annals of Oncology, 2012, 23, ix337.	0.6	0
117	Abstract 1918: Genomic CNV testing on chromosome 17q genes reveals clinically relevant subtypes in breast cancer , 2013, , .		0
118	Abstract P3-05-15: TP53 mutation and nestin protein expression patterns affect the outcome of patients with triple negative breast cancer (TNBC). , 2013, , .		0
119	Evaluation of the prognostic value of p85 protein expression in HER2-positive and HER2-negative patients with advanced breast cancer treated with trastuzumab Journal of Clinical Oncology, 2014, 32, e11577-e11577.	0.8	0
120	Abstract P3-09-07: Prognostic value of immunophenotypically defined subtypes in patients treated with dose-dense sequential adjuvant chemotherapy in the trastuzumab era. A Hellenic Cooperative Oncology Group study. , 2015, , .		0
121	Multigene massively parallel sequencing (MPS) genomic patterns in bilateral breast cancers (BBC) to reveal patient-private disease evolution and heterogeneity Journal of Clinical Oncology, 2015, 33, e22079-e22079.	0.8	0
122	Abstract P4-14-05: Genomic parameters affecting the outcome of patients with advanced breast cancer treated with trastuzumab. , 2016, , .		0
123	Abstract P5-08-50: Associations of MYC protein expression and gene status with breast cancer subtypes and outcome in patients treated with anthracycline-based adjuvant chemotherapy. , 2016, , .		0
124	Abstract P6-09-07: Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer. , 2017, , .		0
125	Lateral cervical lymph node metastasis from papillary thyroid cancer of undetected primary: a case report. Endocrine Abstracts, 0, , .	0.0	0
126	Bortezomib induced purpuric rash. Dermatologic Therapy, 2020, 33, e13651.	0.8	0

#	Article	IF	CITATIONS
127	Dermatoscopy of melanoma according to type, anatomic site and stage. Italian Journal of Dermatology and Venereology, 2021, 156, 274-288.	0.1	0